Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress Replay

Roche has hosted a live audio webcast and conference call on Monday, 22 October 2018.



Daniel O’Day, CEO Roche Pharmaceuticals

ESMO 2018 Key CIT readouts across tumor types

  • IMpassion130: Tecentriq + Abraxane in 1L triple-negative breast cancer

Jakob Dupont, M.D., Global Head Breast & Gyn Cancer Franchise, Pharma Development

  • IMpower130: Tecentriq + Abraxane in 1L non-sq NSCLC

BF1RST: Association between bTMB and Tecentriq efficacy in 1L NSCLC

ALESIA: Alecensa in 1L ALK+ NSCLC in Asian patients

STARTRK2: Entrectinib in NTRK+ solid tumors

GO30140: Tecentriq + Avastin in 1L HCC

Alan Sandler, M.D., Global Head of Lung/Head & Neck Franchise, Pharma Development, a.i. Global Head Oncology

Roche Oncology strategy update

Cynthia Perettie, Head Global Product Strategy Oncology


* Mandatory


The registration form for the webcast is not available.


Please come back 30 minutes before the webcast start date and fill in the registration form.